Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study

Assaf-Harofeh Medical Center

Overview

The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Allergic Conjunctivitis

Interventions

Tacrolimus 0.03% ointment (Protopic)DRUG

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects included if they were \> 5 years old and suffered from intractable allergic conjunctivitis Exclusion Criteria: * pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides

Locations (1)

Assaf Harofeh Medical Center, Department of Ophthalmology

Ẕerifin, Israel

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.